Cargando…

Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study

Real-world evidence plays an important role in the assessment of efficacy and safety of novel therapies. The increasing use of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma has led to notably improved clinical outcomes, while they are also associated with immune-related adve...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuzmanovszki, Daniella, Kiss, Norbert, Tóth, Béla, Kerner, Tünde, Tóth, Veronika, Szakonyi, József, Lőrincz, Kende, Hársing, Judit, Imrédi, Eleonóra, Pfund, Alexa, Szabó, Ákos, Brodszky, Valentin, Rencz, Fanni, Holló, Péter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313334/
https://www.ncbi.nlm.nih.gov/pubmed/35885042
http://dx.doi.org/10.3390/biomedicines10071737
_version_ 1784754054821314560
author Kuzmanovszki, Daniella
Kiss, Norbert
Tóth, Béla
Kerner, Tünde
Tóth, Veronika
Szakonyi, József
Lőrincz, Kende
Hársing, Judit
Imrédi, Eleonóra
Pfund, Alexa
Szabó, Ákos
Brodszky, Valentin
Rencz, Fanni
Holló, Péter
author_facet Kuzmanovszki, Daniella
Kiss, Norbert
Tóth, Béla
Kerner, Tünde
Tóth, Veronika
Szakonyi, József
Lőrincz, Kende
Hársing, Judit
Imrédi, Eleonóra
Pfund, Alexa
Szabó, Ákos
Brodszky, Valentin
Rencz, Fanni
Holló, Péter
author_sort Kuzmanovszki, Daniella
collection PubMed
description Real-world evidence plays an important role in the assessment of efficacy and safety of novel therapies. The increasing use of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma has led to notably improved clinical outcomes, while they are also associated with immune-related adverse events (irAEs). The majority of the available data are based on clinical trials, where the investigated subjects often do not adequately represent the general patient population of the everyday practice. Although there is a niche of objective biomarkers for the future treatment response of ICIs, certain studies suggest that irAEs may be predictive. The aim of this study was to carry out a retrospective analysis of treatment data from patients with advanced melanoma, treated with a single anti-PD-1 agent (pembrolizumab or nivolumab) during a 77-month-long period. Treatment efficacy and occurrence of adverse events were analyzed to identify potential predictive markers. Primary and secondary endpoints were the overall survival (OS) and progression-free survival (PFS). In our cohort, we demonstrated that the occurrence of more than one irAE showed a correlation with response to PD-1 ICI therapy and improved the OS and PFS. Our study suggests, that the grade of toxicity of the irAE may affect the survival rate.
format Online
Article
Text
id pubmed-9313334
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93133342022-07-26 Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study Kuzmanovszki, Daniella Kiss, Norbert Tóth, Béla Kerner, Tünde Tóth, Veronika Szakonyi, József Lőrincz, Kende Hársing, Judit Imrédi, Eleonóra Pfund, Alexa Szabó, Ákos Brodszky, Valentin Rencz, Fanni Holló, Péter Biomedicines Article Real-world evidence plays an important role in the assessment of efficacy and safety of novel therapies. The increasing use of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma has led to notably improved clinical outcomes, while they are also associated with immune-related adverse events (irAEs). The majority of the available data are based on clinical trials, where the investigated subjects often do not adequately represent the general patient population of the everyday practice. Although there is a niche of objective biomarkers for the future treatment response of ICIs, certain studies suggest that irAEs may be predictive. The aim of this study was to carry out a retrospective analysis of treatment data from patients with advanced melanoma, treated with a single anti-PD-1 agent (pembrolizumab or nivolumab) during a 77-month-long period. Treatment efficacy and occurrence of adverse events were analyzed to identify potential predictive markers. Primary and secondary endpoints were the overall survival (OS) and progression-free survival (PFS). In our cohort, we demonstrated that the occurrence of more than one irAE showed a correlation with response to PD-1 ICI therapy and improved the OS and PFS. Our study suggests, that the grade of toxicity of the irAE may affect the survival rate. MDPI 2022-07-19 /pmc/articles/PMC9313334/ /pubmed/35885042 http://dx.doi.org/10.3390/biomedicines10071737 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kuzmanovszki, Daniella
Kiss, Norbert
Tóth, Béla
Kerner, Tünde
Tóth, Veronika
Szakonyi, József
Lőrincz, Kende
Hársing, Judit
Imrédi, Eleonóra
Pfund, Alexa
Szabó, Ákos
Brodszky, Valentin
Rencz, Fanni
Holló, Péter
Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study
title Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study
title_full Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study
title_fullStr Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study
title_full_unstemmed Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study
title_short Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study
title_sort anti-pd-1 monotherapy in advanced melanoma—real-world data from a 77-month-long retrospective observational study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313334/
https://www.ncbi.nlm.nih.gov/pubmed/35885042
http://dx.doi.org/10.3390/biomedicines10071737
work_keys_str_mv AT kuzmanovszkidaniella antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy
AT kissnorbert antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy
AT tothbela antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy
AT kernertunde antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy
AT tothveronika antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy
AT szakonyijozsef antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy
AT lorinczkende antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy
AT harsingjudit antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy
AT imredieleonora antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy
AT pfundalexa antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy
AT szaboakos antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy
AT brodszkyvalentin antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy
AT renczfanni antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy
AT hollopeter antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy